<DOC>
	<DOC>NCT00394823</DOC>
	<brief_summary>The purpose of this study is to assess the impact of supportive measures on the drug adherence of patients with essential hypertension</brief_summary>
	<brief_title>VALIDATE Valsartan and Supportive Measures - Impact on Drug Adherence of Treated Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Male or female patients &gt;= 18 years Females must be either postmenopausal for one year, surgically sterile or using effective contraceptive methods (e.g. barrier method with spermicide, intrauterine device, hormonal contraceptives). Patients with mild essential hypertension: Systolic blood pressure ≥ 140 mmHg and &lt; 170 and/or diastolic blood pressure ≥ 90 mmHg and &lt; 105 mmHg" Moderate and severe hypertension Pregnant or nursing women A history of cardiovascular disease, including angina pectoris, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, transient ischemic attack, stroke, and heart failure NYHA II IV Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Hypertension, valsartan, compliance</keyword>
</DOC>